종양/암 마커 시장

Global Tumor / Cancer Markers Market to Reach US$6.5 Billion by 2030

The global market for Tumor / Cancer Markers estimated at US$4.2 Billion in the year 2023, is expected to reach US$6.5 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 10.6% CAGR

The Tumor / Cancer Markers market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.5 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Tumor / Cancer Markers Market - Key Trends and Drivers Summarized

How Are Tumor and Cancer Markers Revolutionizing Early Detection and Treatment?

Tumor and cancer markers have become indispensable in modern oncology, providing critical insights into the early detection, diagnosis, and management of various cancers. These markers, which are substances often found in higher levels in the blood, urine, or tissue of people with cancer, play a crucial role in identifying the presence and progression of tumors. Tumor markers can be proteins, hormones, or other molecular substances produced either by the cancer cells themselves or by the body in response to cancer. They are particularly useful in detecting specific types of cancers, such as prostate, ovarian, liver, and breast cancer. Early detection through these markers can significantly improve outcomes by allowing for earlier interventions and personalized treatment strategies. In addition to their diagnostic role, cancer markers are also employed in monitoring the effectiveness of treatments and detecting recurrences, making them vital tools throughout a patient’s cancer journey. With the rise of precision medicine, tumor markers are increasingly being used to tailor treatment options based on a patient's unique biological makeup, revolutionizing how cancer is approached.

What Technological Advancements Are Driving the Use of Tumor and Cancer Markers?

Recent technological advancements have greatly enhanced the identification and application of tumor and cancer markers, expanding their utility in both diagnostics and treatment. Improvements in molecular biology techniques, such as next-generation sequencing (NGS), have enabled the detailed analysis of genetic mutations and alterations that contribute to cancer development. This has led to the discovery of new biomarkers that are specific to certain types of cancers, allowing for more precise detection and diagnosis. Liquid biopsy is another significant innovation, allowing clinicians to detect tumor markers through a simple blood sample rather than invasive tissue biopsies. This non-invasive approach enables the detection of circulating tumor DNA (ctDNA) and other markers, providing a real-time view of a patient’s cancer status and making it easier to monitor treatment response and detect early signs of recurrence. Advances in immunohistochemistry (IHC) and enzyme-linked immunosorbent assays (ELISA) have improved the sensitivity and specificity of tests used to measure tumor marker levels, ensuring more accurate results. Additionally, the integration of artificial intelligence (AI) and machine learning into cancer diagnostics is helping to analyze complex datasets and identify patterns that can lead to more accurate prognoses. These technologies are pushing the boundaries of how tumor markers are used, not only in identifying cancers but also in guiding personalized treatment plans and improving patient outcomes.

Why Are Tumor and Cancer Markers Gaining Importance Among Healthcare Providers?

Tumor and cancer markers are gaining increasing importance among healthcare providers because of their ability to provide crucial insights into a patient’s cancer status with relative speed and accuracy. As cancer remains one of the leading causes of death globally, the demand for early detection tools has surged, and tumor markers are at the forefront of this shift. Healthcare providers rely on tumor markers not just for initial diagnoses but also for monitoring the progression of the disease and the effectiveness of treatments. For instance, the prostate-specific antigen (PSA) test is widely used to screen for prostate cancer, while CA-125 is often used to monitor ovarian cancer. In patients undergoing cancer therapy, tumor markers can offer real-time feedback on how well the body is responding to treatment, allowing for timely adjustments in therapy. Moreover, tumor markers play an essential role in assessing the risk of cancer recurrence after treatment. This ability to track and manage cancer over time is critical, especially in cases where cancer may remain dormant for years before returning. As more types of cancer markers are discovered, healthcare providers are increasingly incorporating these tests into routine cancer care, thus improving the personalization of treatment and leading to better overall patient management.

What Factors Are Driving the Growth of the Tumor and Cancer Marker Market?

The growth in the tumor and cancer marker market is being driven by several key factors, each of which is reshaping the field of oncology. One of the most significant drivers is the rising global incidence of cancer, which has created a growing demand for early detection and more effective treatment strategies. As the population ages and lifestyle-related risk factors increase, the need for reliable diagnostic tools like tumor markers has never been more critical. Additionally, advances in molecular diagnostics, including liquid biopsies and genomic sequencing, have opened up new possibilities for using tumor markers in both early detection and ongoing cancer management. The shift toward precision medicine is another major factor driving market growth, as healthcare providers increasingly seek to customize cancer treatments based on the specific biological markers present in individual patients. This personalized approach not only improves the effectiveness of treatments but also reduces unnecessary side effects by tailoring therapies to the patient's genetic profile. The expansion of research and development in oncology has also led to the discovery of new biomarkers, which are being integrated into clinical practice, further fueling the demand for tumor marker testing. Finally, increasing public awareness about the importance of early cancer detection, along with government initiatives to improve cancer screening programs, is supporting the broader adoption of tumor marker tests across healthcare systems. As these trends continue to evolve, the tumor and cancer marker market is expected to grow significantly, playing a pivotal role in the future of cancer care.

Select Competitors (Total 84 Featured) -

• 20/20 Genesystems, Inc.
• Abbott Diagnostics
• AC Immune SA
• Acuamark Diagnostics
• Advanced Cell Diagnostics, Inc.
• Affimedix, Inc.
• Agilent Technologies, Inc.
• Alere, Inc.
• Alexion Pharmaceuticals, Inc.
• ARUP Laboratories

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Tumor / Cancer Markers - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Global Incidence of Cancer Expands Market Opportunity for Tumor and Cancer Markers
  • Growing Focus on Early Cancer Detection Propels Demand for Tumor Marker Testing
  • Technological Advancements in Biomarker Discovery Drive Growth in Cancer Diagnostics
  • Here's How Precision Medicine Accelerates Demand for Specific Tumor Markers in Targeted Therapies
  • Rising Use of Liquid Biopsies Strengthens the Business Case for Non-Invasive Cancer Marker Testing
  • Increasing Adoption of Personalized Cancer Treatment Plans Expands the Role of Tumor Markers
  • Advances in Genomic and Proteomic Technologies Propel Innovation in Cancer Marker Development
  • Growing Prevalence of Companion Diagnostics Generates Demand for Tumor Marker-Based Tests
  • Rising Awareness of Preventive Oncology Boosts Demand for Early-Stage Cancer Marker Detection
  • Expanding Use of AI and Big Data Analytics in Cancer Marker Analysis Propels Growth
  • Growing Focus on Minimally Invasive Testing Strengthens Adoption of Tumor Markers in Routine Screening
  • Here's How the Development of Multimodal Biomarker Panels Expands Opportunities for Comprehensive Cancer Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Tumor / Cancer Markers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Tumor / Cancer Markers Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 5: USA Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 6: USA Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• CANADA
  • TABLE 7: Canada Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 8: Canada Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• JAPAN
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 9: Japan Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 10: Japan Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• CHINA
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 11: China Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 12: China Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• EUROPE
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 13: Europe Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 14: Europe Historic Review for Tumor / Cancer Markers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 15: Europe 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
• FRANCE
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 16: France Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 17: France Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• GERMANY
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 18: Germany Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 19: Germany Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• ITALY
  • TABLE 20: Italy Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Italy Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• UNITED KINGDOM
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 22: UK Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 23: UK Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• SPAIN
  • TABLE 24: Spain Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Spain Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• RUSSIA
  • TABLE 26: Russia Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Russia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• REST OF EUROPE
  • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Rest of Europe Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• ASIA-PACIFIC
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 31: Asia-Pacific Historic Review for Tumor / Cancer Markers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 32: Asia-Pacific 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
• AUSTRALIA
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 33: Australia Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 34: Australia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• INDIA
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 35: India Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: India Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• SOUTH KOREA
  • TABLE 37: South Korea Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 38: South Korea Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• REST OF ASIA-PACIFIC
  • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 40: Rest of Asia-Pacific Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• LATIN AMERICA
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 41: Latin America Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 42: Latin America Historic Review for Tumor / Cancer Markers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Latin America 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 44: Argentina Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Argentina Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• BRAZIL
  • TABLE 46: Brazil Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Brazil Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• MEXICO
  • TABLE 48: Mexico Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Mexico Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• REST OF LATIN AMERICA
  • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of Latin America Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• MIDDLE EAST
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 52: Middle East Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 53: Middle East Historic Review for Tumor / Cancer Markers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 54: Middle East 16-Year Perspective for Tumor / Cancer Markers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
• IRAN
  • TABLE 55: Iran Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 56: Iran Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• ISRAEL
  • TABLE 57: Israel Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 58: Israel Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• SAUDI ARABIA
  • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Saudi Arabia Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• UNITED ARAB EMIRATES
  • TABLE 61: UAE Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 62: UAE Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• REST OF MIDDLE EAST
  • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 64: Rest of Middle East Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
• AFRICA
  • Tumor / Cancer Markers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 65: Africa Recent Past, Current & Future Analysis for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Africa Historic Review for Tumor / Cancer Markers by Segment - Tumor / Cancer Markers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR

IV. COMPETITION